Active substance
Ethambutol
- SFDA 3
- US FDA 5
- Health Canada 2
- US price lines 2
- NHS prices 2
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AFIMOCIL 0.5 GM TAB | 500 mg | Tablet · Oral use | 25 Blister | SAR 13.00 | Generic · Prescription | ALMIRALL PRODES PHARMA S.A. | Withdrawn by MAH · Not Marketed |
| ETHAMBUTOL | 250 mg | Tablet · Oral use | 100 Tablet Container | SAR 29.00 | Generic · Prescription | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Invalid · Not Marketed |
| MYAMBUTOL 400 MG. TABLETS | 400 mg | Tablet · Oral use | 100 Tablet Container | SAR 86.15 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MYAMBUTOL | 100MG; 400MG | tablet · oral | KANCHAN HLTHCARE | Prescription | 6 Nov 1967 |
| ETHAMBUTOL HYDROCHLORIDE | 100MG; 400MG | tablet · oral | EPIC PHARMA LLC | Prescription | 30 Nov 1999 |
| ETHAMBUTOL HYDROCHLORIDE | 100MG; 400MG | tablet · oral | LUPIN | Prescription | 17 Jun 2009 |
| MYAMBUTOL | 200MG; 500MG | tablet · oral | KANCHAN HLTHCARE | Discontinued | 6 Nov 1967 |
| ETHAMBUTOL HYDROCHLORIDE | 400MG | tablet · oral | BARR | Discontinued | 26 Nov 2001 |
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ETHAMBUTOL HCL 100 MG TABLET | $0.30403 | per EA | 23 Sep 2026 |
| US NADAC | ETHAMBUTOL HCL 400 MG TABLET | $0.458 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ethambutol 100mg tablets | £40.00 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Ethambutol 400mg tablets | £50.00 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.5. Antituberculosis medicines · core
Tuberculosis
Oral > Solid > dispersible tablet: 100 mg (EMLc) | Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
Safety signals and safety-related labeling changes
- EMA PRAC 11 Apr 2024 PRAC signal: Drug reaction with eosinophilia and systemic symptoms (DRESS)
Action for MAH: update of the product information: Yes - EMA PRAC 30 Nov 2023 PRAC signal: Drug reaction with eosinophilia and systemic symptoms (DRESS)
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.